1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Catalent, Inc.
  6. Summary
    CTLT   US1488061029

CATALENT, INC.

(CTLT)
  Report
Delayed Nyse  -  04:04 2022-08-12 pm EDT
109.97 USD   +0.03%
08/10Catalent to Acquire Metrics Contract Services for $475 Million
MT
08/09Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity
BU
08/09Catalent, Inc. agreed to acquire Metrics, Inc. from Mayne Pharma, Inc. for $475 million.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
110.04(c) 108.13(c) 112.84(c) 109.94(c) 109.97(c) Last
767 250 609 609 851 176 1 482 919 857 067 Volume
-0.47% -1.74% +4.36% -2.57% +0.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 850 M - -
Net income 2022 481 M - -
Net Debt 2022 3 128 M - -
P/E ratio 2022 40,8x
Yield 2022 -
Sales 2023 5 289 M - -
Net income 2023 595 M - -
Net Debt 2023 2 909 M - -
P/E ratio 2023 34,0x
Yield 2023 -
Capitalization 19 708 M 19 708 M -
EV / Sales 2022 4,71x
EV / Sales 2023 4,28x
Nbr of Employees 17 300
Free-Float 99,7%
More Financials
Company
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - subcontracted manufacturing services (46.4%) - provision of development services (43.9%); - clinical supply services (9.7%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
08/29Earnings Release
More about the company
Ratings of Catalent, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about CATALENT, INC.
08/10Catalent to Acquire Metrics Contract Services for $475 Million
MT
08/09Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Ca..
BU
08/09Catalent, Inc. agreed to acquire Metrics, Inc. from Mayne Pharma, Inc. for $475 million..
CI
08/08Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast
AQ
08/05Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast
BU
07/29INSIDER SELL : Catalent
MT
07/07Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform
MT
07/05Catalent Shifts to Two-Segment Structure; Names Jonathan Arnold Chief Commercial Office..
MT
07/05CATALENT, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina..
AQ
07/05Catalent, Inc. Announces Board Changes
CI
07/05Catalent Announces New Operating Structure
BU
07/05Catalent, Inc. Announces Executive Changes
CI
06/30Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shig..
AQ
06/28ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccin..
AQ
06/28ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to S..
CI
More news
News in other languages on CATALENT, INC.
08/10Catalent va acquérir Metrics Contract Services pour 475 millions de dollars
07/29VENTE D'INITIÉS : Catalent
07/07Xenetic Biosciences signe un accord de fabrication avec l'unité Catalent pour une plate..
07/05Catalent, Inc. annonce des changements au conseil d'administration
07/05Catalent, Inc. annonce des changements de direction
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 109,97 $
Average target price 134,92 $
Spread / Average Target 22,7%
EPS Revisions
Managers and Directors
Alessandro Maselli President, Chief Executive Officer & Director
Thomas P. Castellano Senior VP, Chief Financial & Accounting Officer
John R. Chiminski Executive Chairman
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.-14.11%19 708
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131